Healing / repair

Larazotide

In clinical trials

Larazotide acetate (AT-1001) · Tight-junction regulator (zonulin antagonist)

Gut-barrier peptide trialed for celiac disease.

Half-life

Acts locally (minimal absorption)

Route

Oral

Evidence

In clinical trials — reached Phase 3 for celiac (did not meet primary endpoint). Not approved.

What it is

An orally-acting peptide that tightens intestinal junctions, investigated as an adjunct for celiac disease ('leaky gut').

How it works

Antagonizes zonulin to reduce intestinal permeability and tighten the gut barrier; acts locally in the gut, not absorbed.

Studied for

Celiac disease (adjunct to gluten-free diet); intestinal permeability.

Regulatory status

Investigational; not FDA-approved.

Safety

Generally well tolerated in trials; headache and GI symptoms reported.

Reconstitution calculator →

Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.